Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Grant, J. E. Articles by Kallio, A. Search for Related Content PubMed Citation Articles by Grant, J. E. Articles by Kallio, A. Impulse Control Disorders Other Somatic Therapy

Multicenter Investigation of the Opioid Antagonist Nalmefene in the Treatment of Pathological Gambling

OBJECTIVE: Pathological gambling is a disabling disorder experienced by approximately 1%–2% of adults and for which there are few empirically validated treatments. The authors examined the efficacy and tolerability of the opioid antagonist nalmefene in the treatment of adults with pathological gambling. METHOD: A 16-week, randomized, dose-ranging, double-blind, placebo-controlled trial was conducted at 15 outpatient treatment centers across the United States between March 2002 and April 2003. Two hundred seven persons with DSM-IV pathological gambling were randomly assigned to receive nalmefene (25 mg/day, 50 mg/day, or 100 mg/day) or placebo. Scores on the primary outcome measure (Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling) were analyzed by using a linear mixed-effects model. RESULTS: Estimated regression coefficients showed that the 25 mg/day and 50 mg/day nalmefene groups had significantly different scores on the Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling, compared to the placebo group. A total of 59.2% of the subjects who received 25 mg/day of nalmefene were rated as "much improved" or "very much improved" at the last evaluation, compared to 34.0% of those who received placebo. Adverse experiences included nausea, dizziness, and insomnia. CONCLUSIONS: Subjects who received nalmefene had a statistically significant reduction in severity of pathological gambling. Low-dose nalmefene (25 mg/day) appeared efficacious and was associated with few adverse events. Higher doses (50 mg/day and 100 mg/day) resulted in intolerable side effects.

This article has been cited by other articles:

				P. Petrovic, B. Pleger, B. Seymour, S. Kloppel, B. De Martino, H. Critchley, and R. J. Dolan Blocking Central Opiate Function Modulates Hedonic Impact and Anterior Cingulate Response to Rewards and Losses J. Neurosci., October 15, 2008; 28(42): 10509 - 10516. [Abstract] [Full Text] [PDF]

				M. N Potenza The neurobiology of pathological gambling and drug addiction: an overview and new findings Phil Trans R Soc B, October 12, 2008; 363(1507): 3181 - 3189. [Abstract] [Full Text] [PDF]

				C. Blanco, J. Grant, N. M. Petry, H. B. Simpson, A. Alegria, S.-M. Liu, and D. Hasin Prevalence and Correlates of Shoplifting in the United States: Results From the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Am J Psychiatry, July 1, 2008; 165(7): 905 - 913. [Abstract] [Full Text] [PDF]

				S. H Wong and M. J Steiger Pathological gambling in Parkinson's disease BMJ, April 21, 2007; 334(7598): 810 - 811. [Full Text] [PDF]

				Opioid Antagonist Reduces Severity of Pathological Gambling Journal Watch (General), February 21, 2006; 2006(221): 6 - 6. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us